bleomycin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 4742 11056-06-7

Description:

MoleculeDescription

Synonyms:

  • bleomycin
  • bleomycins
  • bleomycin sulfate
  • bleomycin hydrochloride
  • bleomycin HCl
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
  • Molecular weight: 2841.07
  • Formula: C110H168N37O42S5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 688.97
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.43 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.26 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 31, 1973 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 267 25.39 164 6547 97503 50500910
Pulmonary toxicity 200.52 25.39 59 6652 5503 50592910
Neutropenia 192.64 25.39 158 6553 147807 50450606
Ovarian germ cell teratoma 146.62 25.39 22 6689 56 50598357
Teratoma 127.16 25.39 21 6690 116 50598297
Second primary malignancy 115.85 25.39 41 6670 6873 50591540
Acute myeloid leukaemia 91.07 25.39 43 6668 15031 50583382
Deafness 86.41 25.39 42 6669 15649 50582764
Mucosal inflammation 86.05 25.39 58 6653 40084 50558329
Teratoma benign 80.66 25.39 13 6698 60 50598353
Myelodysplastic syndrome 78.82 25.39 39 6672 15093 50583320
Product use in unapproved indication 74.44 25.39 84 6627 115735 50482678
Hepatitis B reactivation 70.22 25.39 21 6690 2066 50596347
Bone marrow failure 69.16 25.39 44 6667 27580 50570833
Interstitial lung disease 65.20 25.39 55 6656 53121 50545292
Pulmonary fibrosis 63.87 25.39 40 6671 24397 50574016
Cutaneous calcification 63.17 25.39 11 6700 87 50598326
Febrile bone marrow aplasia 60.80 25.39 25 6686 6286 50592127
Chloroma 60.77 25.39 12 6699 199 50598214
Respiratory symptom 58.93 25.39 19 6692 2395 50596018
Pancytopenia 55.75 25.39 62 6649 83968 50514445
Tissue infiltration 54.40 25.39 13 6698 540 50597873
Premature baby 52.97 25.39 32 6679 18305 50580108
Basal ganglion degeneration 52.89 25.39 12 6699 396 50598017
Necrotising gastritis 52.17 25.39 9 6702 67 50598346
Drug resistance 51.93 25.39 32 6679 18957 50579456
Acute respiratory distress syndrome 51.30 25.39 33 6678 21066 50577347
Respiratory failure 48.37 25.39 60 6651 91121 50507292
Lung disorder 46.18 25.39 42 6669 44757 50553656
Uterine enlargement 45.93 25.39 13 6698 1053 50597360
Thrombocytopenia 45.08 25.39 69 6642 127604 50470809
Exposure during pregnancy 43.56 25.39 66 6645 120949 50477464
Foetal exposure during pregnancy 43.55 25.39 33 6678 27326 50571087
Peripheral sensory neuropathy 43.51 25.39 20 6691 6571 50591842
Aplasia 43.28 25.39 17 6694 3796 50594617
Combined immunodeficiency 42.19 25.39 8 6703 106 50598307
Sarcoidosis 42.05 25.39 18 6693 4999 50593414
Primary immunodeficiency syndrome 41.74 25.39 7 6704 43 50598370
Disease progression 41.38 25.39 57 6654 95809 50502604
Premature menopause 40.31 25.39 11 6700 779 50597634
Inguinal hernia 39.90 25.39 13 6698 1693 50596720
Malignant neoplasm progression 39.65 25.39 47 6664 68077 50530336
Hyperpyrexia 39.62 25.39 15 6696 3034 50595379
Flagellate dermatitis 38.50 25.39 8 6703 173 50598240
Vulvovaginal inflammation 38.39 25.39 10 6701 592 50597821
Anaesthesia 38.21 25.39 9 6702 351 50598062
Anaemia 37.84 25.39 95 6616 252361 50346052
Leukaemia 37.62 25.39 15 6696 3484 50594929
Acute hepatic failure 36.82 25.39 24 6687 15653 50582760
Psychogenic seizure 36.76 25.39 12 6699 1573 50596840
Cardiotoxicity 36.25 25.39 18 6693 7009 50591404
Septic shock 35.86 25.39 41 6670 57134 50541279
Haemophagocytic lymphohistiocytosis 35.54 25.39 19 6692 8614 50589799
Tumour lysis syndrome 35.32 25.39 18 6693 7403 50591010
Dysaesthesia 33.29 25.39 14 6697 3721 50594692
Transdifferentiation of neoplasm 33.24 25.39 5 6706 13 50598400
Encephalitis viral 32.67 25.39 11 6700 1586 50596827
Neurological decompensation 32.54 25.39 12 6699 2258 50596155
Lymphopenia 32.08 25.39 22 6689 15599 50582814
Hypochromic anaemia 32.02 25.39 11 6700 1685 50596728
Pleuroparenchymal fibroelastosis 32.02 25.39 5 6706 18 50598395
Capillary leak syndrome 30.86 25.39 11 6700 1879 50596534
Acute promyelocytic leukaemia 30.19 25.39 9 6702 875 50597538
Monoplegia 30.16 25.39 12 6699 2771 50595642
Myelosuppression 30.06 25.39 20 6691 13497 50584916
Traumatic lung injury 29.77 25.39 10 6701 1431 50596982
Abdominal compartment syndrome 29.72 25.39 8 6703 538 50597875
Off label use 29.09 25.39 132 6579 474294 50124119
Rash 28.89 25.39 11 6700 437460 50160953
Pain 28.78 25.39 21 6690 578882 50019531
Meningitis streptococcal 28.12 25.39 6 6705 148 50598265
Acute lymphocytic leukaemia 25.46 25.39 10 6701 2231 50596182

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 403.46 22.85 307 8759 111933 29453528
Second primary malignancy 318.57 22.85 107 8959 6598 29558863
Pulmonary toxicity 236.04 22.85 79 8987 4811 29560650
Acute myeloid leukaemia 225.10 22.85 107 8959 16406 29549055
Azoospermia 140.30 22.85 31 9035 374 29565087
Pulmonary fibrosis 128.36 22.85 72 8994 15510 29549951
Pneumonitis 118.68 22.85 85 8981 27959 29537502
Myelodysplastic syndrome 114.33 22.85 70 8996 17724 29547737
Interstitial lung disease 112.86 22.85 112 8954 57606 29507855
Neutropenia 104.28 22.85 162 8904 131549 29433912
Acute respiratory distress syndrome 86.78 22.85 65 9001 22870 29542591
Cardiotoxicity 74.68 22.85 34 9032 4710 29560751
Flagellate dermatitis 73.33 22.85 12 9054 20 29565441
Bone marrow failure 72.41 22.85 63 9003 27386 29538075
Traumatic lung injury 68.76 22.85 22 9044 1158 29564303
Endocarditis noninfective 68.33 22.85 14 9052 114 29565347
Papillary thyroid cancer 60.66 22.85 17 9049 565 29564896
Pneumomediastinum 60.19 22.85 22 9044 1734 29563727
Pyrexia 57.76 22.85 206 8860 287416 29278045
Chronic myeloid leukaemia 53.91 22.85 21 9045 1973 29563488
Respiratory failure 53.66 22.85 102 8964 97029 29468432
Pneumocystis jirovecii pneumonia 53.53 22.85 43 9023 16736 29548725
Cytomegalovirus chorioretinitis 53.47 22.85 24 9042 3214 29562247
Testicular disorder 51.41 22.85 15 9051 577 29564884
Vena cava thrombosis 51.29 22.85 17 9049 1001 29564460
Lung disorder 48.61 22.85 53 9013 30309 29535152
Thrombocytopenia 47.45 22.85 118 8948 134705 29430756
Coronary artery thrombosis 46.83 22.85 19 9047 1986 29563475
Scleroderma 46.74 22.85 17 9049 1321 29564140
Off label use 46.15 22.85 198 8868 300602 29264859
Pneumothorax 45.10 22.85 38 9028 15804 29549657
Osteonecrosis 43.87 22.85 35 9031 13484 29551977
Myositis 43.06 22.85 31 9035 10252 29555209
Product use in unapproved indication 42.83 22.85 87 8979 86788 29478673
Leukopenia 42.26 22.85 67 8999 55136 29510325
Chloroma 40.82 22.85 12 9054 474 29564987
Teratoma 39.94 22.85 7 9059 21 29565440
Subcutaneous emphysema 39.93 22.85 14 9052 978 29564483
Pulmonary embolism 39.33 22.85 78 8988 76456 29489005
Deafness 39.13 22.85 29 9037 10026 29555435
Malignant neoplasm progression 38.83 22.85 76 8990 73783 29491678
Autoimmune neutropenia 37.85 22.85 10 9056 265 29565196
Blood pressure decreased 37.31 22.85 57 9009 45420 29520041
Pancytopenia 37.14 22.85 80 8986 83088 29482373
Haematotoxicity 37.08 22.85 24 9042 6675 29558786
Mucosal inflammation 37 22.85 47 9019 31548 29533913
Taeniasis 34.73 22.85 7 9059 52 29565409
Acute myocardial infarction 33.28 22.85 56 9010 48382 29517079
Premature ageing 32.02 22.85 7 9059 80 29565381
Carotid artery thrombosis 31.16 22.85 9 9057 334 29565127
Neutropenic sepsis 31.07 22.85 27 9039 11700 29553761
Lung infiltration 30.96 22.85 27 9039 11752 29553709
Cerebral infarction 30.95 22.85 38 9028 24637 29540824
Osteosarcoma 30.92 22.85 8 9058 195 29565266
Ichthyosis 30.78 22.85 7 9059 97 29565364
Vascular access site occlusion 29.72 22.85 6 9060 45 29565416
Testicular malignant teratoma 29.64 22.85 5 9061 11 29565450
Pneumonia salmonella 29.27 22.85 6 9060 49 29565412
Fall 29.25 22.85 9 9057 177169 29388292
Dizziness 28.95 22.85 11 9055 189673 29375788
Septic shock 28.86 22.85 61 9005 62499 29502962
Vocal cord inflammation 28.65 22.85 6 9060 55 29565406
Cardiac dysfunction 28.59 22.85 13 9053 1794 29563667
Splenic infarction 28.37 22.85 13 9053 1826 29563635
Therapy partial responder 27.25 22.85 18 9048 5181 29560280
Rash 25.82 22.85 13 9053 189806 29375655
Cerebral venous thrombosis 25.66 22.85 9 9057 629 29564832
Organising pneumonia 25.30 22.85 17 9049 5031 29560430
Paternal exposure timing unspecified 25.19 22.85 5 9061 34 29565427
Ischaemic cerebral infarction 25.11 22.85 10 9056 995 29564466
Arterial thrombosis 24.91 22.85 11 9055 1417 29564044
Acute promyelocytic leukaemia 24.52 22.85 8 9058 448 29565013
Sarcoidosis 23.91 22.85 13 9053 2627 29562834
Spindle cell sarcoma 23.90 22.85 6 9060 129 29565332
Death 23.75 22.85 43 9023 342041 29223420
Cerebral artery stenosis 23.51 22.85 7 9059 289 29565172
Subdural haemorrhage 23.05 22.85 13 9053 2822 29562639
Pain 22.92 22.85 12 9054 171420 29394041

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 658.74 20.73 446 13875 187211 64297200
Second primary malignancy 414.15 20.73 140 14181 12197 64472214
Pulmonary toxicity 371.52 20.73 118 14203 8443 64475968
Acute myeloid leukaemia 340.45 20.73 151 14170 27312 64457099
Neutropenia 258.66 20.73 291 14030 239333 64245078
Myelodysplastic syndrome 197.01 20.73 104 14217 27475 64456936
Interstitial lung disease 176.04 20.73 157 14164 97575 64386836
Pulmonary fibrosis 172.82 20.73 98 14223 29780 64454631
Teratoma 147.05 20.73 26 14295 125 64484286
Ovarian germ cell teratoma 135.27 20.73 22 14299 56 64484355
Acute respiratory distress syndrome 134.45 20.73 92 14229 38843 64445568
Pneumonitis 128.35 20.73 99 14222 50266 64434145
Bone marrow failure 121.62 20.73 94 14227 47858 64436553
Pancytopenia 101.14 20.73 141 14180 143168 64341243
Thrombocytopenia 100.68 20.73 179 14142 223622 64260789
Flagellate dermatitis 100.36 20.73 20 14301 200 64484211
Mucosal inflammation 99.82 20.73 94 14227 62490 64421921
Teratoma benign 99.50 20.73 17 14304 64 64484347
Respiratory failure 96.91 20.73 147 14174 161036 64323375
Malignant neoplasm progression 96.48 20.73 122 14199 112749 64371662
Lung disorder 92.68 20.73 89 14232 60611 64423800
Pneumocystis jirovecii pneumonia 92.32 20.73 64 14257 27570 64456841
Product use in unapproved indication 90.88 20.73 150 14171 176468 64307943
Peripheral sensory neuropathy 87.19 20.73 45 14276 11333 64473078
Chloroma 86.98 20.73 22 14299 683 64483728
Traumatic lung injury 84.94 20.73 28 14293 2248 64482163
Pneumomediastinum 78.30 20.73 28 14293 2872 64481539
Chronic myeloid leukaemia 74.16 20.73 28 14293 3346 64481065
Pyrexia 71.23 20.73 278 14043 558366 63926045
Cardiotoxicity 71.22 20.73 38 14283 10236 64474175
Haematotoxicity 71.04 20.73 41 14280 12855 64471556
Endocarditis noninfective 66.46 20.73 14 14307 188 64484223
Sarcoidosis 64.10 20.73 30 14291 6116 64478295
Off label use 62.18 20.73 291 14030 632515 63851896
Myelitis 55.52 20.73 20 14301 2094 64482317
Cutaneous calcification 55.47 20.73 11 14310 107 64484304
Disease progression 54.42 20.73 106 14215 141574 64342837
Pain 53.80 20.73 28 14293 553483 63930928
Pneumothorax 53.79 20.73 44 14277 24254 64460157
Necrotising gastritis 52.87 20.73 10 14311 74 64484337
Acute promyelocytic leukaemia 51.49 20.73 17 14304 1371 64483040
Rash 49.50 20.73 20 14301 458529 64025882
Subcutaneous emphysema 49.03 20.73 17 14304 1592 64482819
Osteonecrosis 48.06 20.73 44 14277 28185 64456226
Septic shock 46.86 20.73 84 14237 105353 64379058
Papillary thyroid cancer 46.66 20.73 18 14303 2280 64482131
Deafness 46.53 20.73 36 14285 18323 64466088
Coronary artery thrombosis 46.16 20.73 19 14302 2850 64481561
Stem cell transplant 45.85 20.73 20 14301 3461 64480950
Febrile bone marrow aplasia 44.61 20.73 29 14292 11226 64473185
Leukopenia 44.15 20.73 80 14241 101162 64383249
Cytomegalovirus chorioretinitis 42.22 20.73 21 14300 4891 64479520
Therapy partial responder 42.09 20.73 27 14294 10221 64474190
Haemophagocytic lymphohistiocytosis 41.33 20.73 33 14288 17576 64466835
Tumour lysis syndrome 40.52 20.73 34 14287 19406 64465005
Myositis 39.10 20.73 31 14290 16346 64468065
Acute lymphocytic leukaemia 38.50 20.73 19 14302 4352 64480059
Myelosuppression 38.35 20.73 36 14285 23794 64460617
Combined immunodeficiency 38.22 20.73 8 14313 104 64484307
Tissue infiltration 37.82 20.73 11 14310 582 64483829
Basal ganglion degeneration 37.13 20.73 10 14311 398 64484013
Taeniasis 36.98 20.73 7 14314 52 64484359
Autoimmune neutropenia 36.89 20.73 10 14311 408 64484003
Azoospermia 35.94 20.73 8 14313 141 64484270
Vulvovaginal inflammation 35.53 20.73 10 14311 470 64483941
Pleuroparenchymal fibroelastosis 35.46 20.73 6 14315 21 64484390
Primary immunodeficiency syndrome 35.40 20.73 7 14314 67 64484344
Fall 34.99 20.73 25 14296 416801 64067610
Vena cava thrombosis 34.94 20.73 15 14306 2497 64481914
Uterine enlargement 34.83 20.73 11 14310 770 64483641
Scleroderma 33.89 20.73 18 14303 4800 64479611
Premature ageing 33.80 20.73 7 14314 86 64484325
Leukaemia 32.97 20.73 18 14303 5070 64479341
Cerebral infarction 32.87 20.73 43 14278 41001 64443410
Aplasia 32.79 20.73 20 14301 6933 64477478
Lung infiltration 32.55 20.73 31 14290 20858 64463553
Cerebral venous thrombosis 32.07 20.73 14 14307 2427 64481984
Joint swelling 31.60 20.73 5 14316 215377 64269034
Acute myocardial infarction 31.54 20.73 56 14265 69662 64414749
Bacterial infection 31.46 20.73 33 14288 24917 64459494
Ichthyosis 31.31 20.73 7 14314 126 64484285
Testicular malignant teratoma 31.25 20.73 5 14316 11 64484400
Pneumonia salmonella 31.20 20.73 6 14315 49 64484362
Weight increased 31.19 20.73 5 14316 213343 64271068
Hepatitis B reactivation 30.86 20.73 17 14304 4872 64479539
Respiratory disorder 30.75 20.73 39 14282 36072 64448339
Organising pneumonia 30.29 20.73 21 14300 9034 64475377
Diarrhoea 30.24 20.73 73 14248 722631 63761780
Vascular access site occlusion 30.11 20.73 6 14315 60 64484351
Anaemia 29.20 20.73 163 14158 378517 64105894
Hodgkin's disease recurrent 28.83 20.73 5 14316 21 64484390
Peripheral sensorimotor neuropathy 28.14 20.73 13 14308 2572 64481839
Cytopenia 28.07 20.73 25 14296 15446 64468965
Blood pressure decreased 27.75 20.73 60 14261 86139 64398272
Anaesthesia 27.73 20.73 8 14313 411 64484000
Hyperpyrexia 27.58 20.73 16 14305 5061 64479350
Ototoxicity 27.50 20.73 13 14308 2710 64481701
Fatigue 27.26 20.73 81 14240 748649 63735762
Anxiety 26.96 20.73 6 14315 202643 64281768
Neoplasm progression 26.90 20.73 39 14282 40925 64443486
Pulmonary embolism 26.48 20.73 82 14239 146274 64338137
Left ventricular dysfunction 26.11 20.73 25 14296 16929 64467482
Encephalitis viral 26.01 20.73 12 14309 2368 64482043
B precursor type acute leukaemia 25.68 20.73 7 14314 292 64484119
Psychogenic seizure 25.63 20.73 11 14310 1830 64482581
Lymphopenia 25.56 20.73 30 14291 25627 64458784
Dizziness 25.50 20.73 35 14286 430128 64054283
Splenic infarction 25.29 20.73 13 14308 3244 64481167
Swelling 25.19 20.73 3 14318 160215 64324196
Death 25.05 20.73 43 14278 482662 64001749
Testicular cancer metastatic 24.49 20.73 5 14316 57 64484354
Hypothyroidism 24.39 20.73 37 14284 40420 64443991
Arthralgia 24.25 20.73 38 14283 442222 64042189
Nasopharyngitis 23.79 20.73 7 14314 196066 64288345
Blood pressure increased 23.17 20.73 5 14316 172547 64311864
Vocal cord inflammation 22.94 20.73 6 14315 213 64484198
Arterial thrombosis 22.71 20.73 11 14310 2419 64481992
Spindle cell sarcoma 22.68 20.73 6 14315 223 64484188
Carotid artery thrombosis 22.63 20.73 10 14311 1785 64482626
Sinusitis 22.29 20.73 3 14318 145925 64338486
Urinary tract infection 22.02 20.73 12 14309 231584 64252827
Oropharyngeal squamous cell carcinoma 21.99 20.73 6 14315 251 64484160
Transdifferentiation of neoplasm 21.91 20.73 5 14316 99 64484312
Venoocclusive liver disease 21.87 20.73 18 14303 9997 64474414
Monoplegia 21.81 20.73 12 14309 3431 64480980
Lymphadenopathy 21.76 20.73 38 14283 46648 64437763
Hodgkin's disease nodular sclerosis 21.73 20.73 4 14317 25 64484386
Abdominal compartment syndrome 21.43 20.73 9 14312 1419 64482992
Neuropathy peripheral 21.39 20.73 66 14255 117459 64366952
Ischaemic cerebral infarction 21.25 20.73 10 14311 2062 64482349
Abdominal discomfort 21.24 20.73 7 14314 182315 64302096
Pruritus 21.05 20.73 23 14298 312377 64172034
Drug resistance 21.01 20.73 32 14289 35070 64449341
Osteosarcoma 20.95 20.73 6 14315 300 64484111

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35610 antineoplastic agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000180854 Cytoprotective Agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diffuse non-Hodgkin's lymphoma, large cell indication 109969005
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Malignant tumor of head and/or neck indication 255056009
Follicular non-Hodgkin's lymphoma indication 308121000
Malignant tumor of cervix indication 363354003 DOID:4362
Malignant tumor of penis indication 363516004 DOID:11615
International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma indication 385370007
Squamous cell carcinoma indication 402815007 DOID:1749
Pleural Malignant Effusions indication
Testicular Germ Cell Tumor indication
Mycosis fungoides off-label use 118618005
Ovarian Germ Cell Tumor Carcinoma off-label use




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aspartyl/asparaginyl beta-hydroxylase Enzyme IC50 5.83 CHEMBL

External reference:

IDSource
D02177 KEGG_DRUG
4019637 VUID
N0000147730 NUI
9041-93-4 SECONDARY_CAS_RN
67763-87-5 SECONDARY_CAS_RN
4018135 VANDF
4019637 VANDF
CHEBI:3139 CHEBI
CHEMBL403664 ChEMBL_ID
CHEMBL3085504 ChEMBL_ID
2721 INN_ID
DB00290 DRUGBANK_ID
40S1VHN69B UNII
5360373 PUBCHEM_CID
1621 RXNORM
4293 MMSL
9784 MMSL
d00177 MMSL
002661 NDDF
004820 NDDF
009872 NDDF
15660006 SNOMEDCT_US
372843005 SNOMEDCT_US
703085003 SNOMEDCT_US
76591000 SNOMEDCT_US
D001761 MESH_DESCRIPTOR_UI
C0005740 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9240 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9240 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9241 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9241 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-3154 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 19 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0703-3155 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 19 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-886 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-908 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-136 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-137 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 69097-364 INJECTION 15 [USPU] INTRAMUSCULAR ANDA 20 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 70121-1567 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15000 [iU] INTRA-ARTERIAL UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 18 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-106 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 24 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-107 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 24 sections